Legal Representation
Attorney
Mary Frances Love
USPTO Deadlines
Next Deadline
1427 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-06-13)
Due Date
June 13, 2029
Grace Period Ends
December 13, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
31 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jun 13, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
Jun 13, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
May 9, 2023 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
May 8, 2023 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
May 4, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
May 4, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
Apr 18, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
Apr 18, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
Oct 18, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Aug 23, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Aug 23, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Aug 3, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Jul 15, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Jul 14, 2022 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
Jul 14, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Jul 14, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Feb 1, 2022 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
Feb 1, 2022 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
Feb 1, 2022 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
Jan 20, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Jan 20, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Jan 20, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Aug 5, 2021 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
Aug 5, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Aug 5, 2021 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
Jul 28, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jul 28, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Jul 28, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Jul 21, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Apr 12, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Jan 15, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical agents for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; pharmaceutical preparations for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; pharmaceuticals for the treatment of hereditary angioedema all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; Veterinary preparations for treatment of intestinal bacteria; veterinary preparations, namely, antioxidants; veterinary preparations, namely, pain relief medications; veterinary preparations for medical treatment of chronic illnesses; veterinary preparations for treatment of viral diseases; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; dietary supplements for humans and animals; supplements for the treatment of hereditary angioedema; supplements for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; food for babies; medical dressings; plasters for medical purposes; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; biological preparations for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels and transdermal patches; chemical preparations for the medical treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels and transdermal patches; Drug delivery agents consisting of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents for use in pharmaceutical preparations, drugs and medicines for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; medical drugs for the treatment of rare diseases, in particular for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; enzyme preparations for medical purposes, enzyme preparations for the treatment of hereditary angioedema, medical enzyme preparations in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; enzyme preparations for veterinary purposes; medicinal preparations for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; medicines for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; Medical and veterinary preparations and articles, namely, pre-filled syringes containing a bradykinin B2 receptor antagonist for medical purposes; Pharmaceuticals and natural remedy preparations, for use in the treatment and management of hereditary angioedema; single-use pre-filled syringes containing a bradykinin B2 receptor antagonist; syringes sold filled with a bradykinin B2 receptor antagonist for subcutaneous injections in the treatment of acute attack of hereditary angioedema; single-use pre-filled syringes containing a bradykinin B2 receptor antagonist for subcutaneous injections in the treatment of acute attack of hereditary angioedema
First Use Anywhere:
Sep 23, 2022
First Use in Commerce:
Sep 23, 2022
Additional Information
Translation
The wording SAJAZIR has no meaning in a foreign language.
Classification
International Classes
005